Compounds > muramyl dipeptide
Page last updated: 2024-11-08

muramyl dipeptide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID451714
CHEMBL ID369794
CHEBI ID59414
SCHEMBL ID41814

Synonyms (21)

Synonym
d-.alpha.-glutamine, n2-[n-(n-acetyl-.beta.-allo-muramoyl)-l-alanyl]-
n-acetyl-muramyl-l-alanyl-d-isoglutamine
(4r)-4-[[(2s)-2-[[(2r)-2-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxo-pentanoic acid
87420-48-2
muramyldipeptide
acetylmuramyl-alanyl-iso-glutamine
(4r)-4-[[(2s)-2-[[(2r)-2-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoic acid
CHEBI:59414 ,
acetylmuramyl-l-alanyl-d-isoglutamine
murnac-l-ala-gamma-d-glu
CHEMBL369794
d-alpha-glutamine, n2-(n-(n-acetyl-beta-allo-muramoyl)-l-alanyl)-
gtpl5024
3lt ,
(4r)-4-[[(2s)-2-[[(2r)-2-[(2r,3s,4r,5r,6r)-5-acetamido-2-(hydroxymethyl)-3,6-bis(oxidanyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-azanyl-5-oxidanylidene-pentanoic acid
SCHEMBL41814
bdbm50164885
(4r)-4-{[(2s)-2-{[(2r)-2-{[(2r,3r,4r,5s,6r)-3-(acetylamino)-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-4-yl]oxy}propanoyl]amino}propanoyl]amino}-5-amino-5-oxopentanoic acid (non-preferred name)
Q27453912
DTXSID101007551
3-o-[1-({1-[(4-carboxy-1-hydroxy-1-iminobutan-2-yl)imino]-1-hydroxypropan-2-yl}imino)-1-hydroxypropan-2-yl]-2-deoxy-2-[(1-hydroxyethylidene)amino]hexopyranose
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
immunological adjuvantA substance that augments, stimulates, activates, potentiates, or modulates the immune response at either the cellular or humoral level. A classical agent (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contains bacterial antigens. It could also be endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Its mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy is related to its antigen-specific immunoadjuvanticity.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
glycopeptideAny carbohydrate derivative that consists of glycan moieties covalently attached to the side chains of the amino acid residues that constitute the peptide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (6)

PathwayProteinsCompounds
Immune System91482
Innate Immune System41475
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways335
NOD1/2 Signaling Pathway174
Inflammasomes163
The NLRP1 inflammasome12

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)EC50 (µMol)0.09530.04600.09530.1480AID1297588; AID1469591; AID1817382
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (79)

Processvia Protein(s)Taxonomy
positive regulation of interleukin-10 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of JNK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
temperature homeostasisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
pattern recognition receptor signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
innate immune response in mucosaNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
adaptive immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of dendritic cell antigen processing and presentationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of T cell mediated immunityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of cytokine production involved in immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of dendritic cell cytokine productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
biosynthetic process of antibacterial peptides active against Gram-positive bacteriaNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of type 2 immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulinNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
phagocytosisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
defense responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of biosynthetic process of antibacterial peptides active against Gram-positive bacteriaNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
JNK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to nutrientNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of biotic stimulusNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of macrophage cytokine productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of bacteriumNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
maintenance of gastrointestinal epitheliumNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
regulation of appetiteNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
detection of muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of type II interferon productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of interleukin-12 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of interleukin-18 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of interleukin-2 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-1 beta productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-12 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-17 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-6 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of interleukin-8 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of tumor necrosis factor productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
toll-like receptor 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of toll-like receptor 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to endoplasmic reticulum stressNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
intracellular signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
intestinal stem cell homeostasisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
defense response to bacteriumNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
response to exogenous dsRNANucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of MAPK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
innate immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of Notch signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of gamma-delta T cell activationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
host-mediated regulation of intestinal microbiota compositionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of epithelial cell proliferationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
regulation of inflammatory responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of phagocytosisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of B cell activationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
stress-activated MAPK cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
establishment of localization in cellNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of macrophage cytokine productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
nucleotide-binding oligomerization domain containing 2 signaling pathwayNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to lipopolysaccharideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to peptidoglycanNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to muramyl dipeptideNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cellular response to organic cyclic compoundNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
regulation of neutrophil chemotaxisNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
xenophagyNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
antibacterial innate immune responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of mitophagyNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of protein K63-linked ubiquitinationNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
positive regulation of xenophagyNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
negative regulation of macrophage apoptotic processNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
actin bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ATP bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
enzyme bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein kinase bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
Hsp70 protein bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
muramyl dipeptide bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
pattern recognition receptor activityNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
peptidoglycan bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ubiquitin bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
ADP bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein-containing complex bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
CARD domain bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
Hsp90 protein bindingNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
cytosolNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
extrinsic component of plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cytoplasmNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
mitochondrionNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
Golgi apparatusNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cytosolNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cytoskeletonNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
cell surfaceNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
basolateral plasma membraneNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
vesicleNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
phagocytic vesicleNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
protein-containing complexNucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (95)

Assay IDTitleYearJournalArticle
AID78217Ability of I-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 1 ug/mL concentration in expt 21983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID75983Ability of P-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 1 ug/mL concentration in expt 31983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1469609Immunostimulatory activity in human PBMC assessed as increase in IL-4 release at 2 uM after 18 hrs in presence of LPS by flow cytometry2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID75985Ability of P-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 10 ug/mL concentration in expt 41983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1297586Agonist activity at NOD2 receptor (unknown origin) expressed in HEK-Blue cells assessed as NF-kappaB transcriptional activity at 20 uM after 18 hrs by secreted embryonic alkaline phosphatase reporter gene assay relative to untreated control2016European journal of medicinal chemistry, Jun-30, Volume: 116Structural requirements of acylated Gly-l-Ala-d-Glu analogs for activation of the innate immune receptor NOD2.
AID1817387Immunostimulatory activity in human PBMC cells assessed as increase in LPS-induced IL-1beta production at 2 uM incubated for 18 hrs by flow cytometry analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID75984Ability of P-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 1 ug/mL concentration in expt 41983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1817404Cytotoxicity against HEK-Blue hNOD2 cells assessed as reduction in metabolic activity at 20 uM incubated for 18 hrs by MTS assay2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID113920Tested for antibody response of mice injected with Bovine serum Albumin(BSA) at 50 ug/dose in experiment 61982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
AID113916Tested for antibody response of mice injected with Bovine serum Albumin(BSA) at 50 ug/dose in experiment 21982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
AID94078Protective activity against Klebsiella pneumoniae was measured as number of survivors to the number of total animals used;15/241982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides.
AID77671Ability of P-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 10 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1469604Immunostimulatory activity in human PBMC assessed as increase in IL-10 release at 2 uM after 18 hrs by flow cytometry2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID615227Immunomodulatory effect in human THP1 cells assessed as increase in LPS-induced TNF-alpha release at 2 uM after 24 hrs by sandwich ELISA relative to LPS2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
AID1469614Immunoadjuvant activity in ovalbumin-induced NIH/OlaHsd mouse model of adjuvancy assessed as modulation of Th1/Th2-bias of induced immune response by measuring ratio of anti-OVA IgG1 to anti-OVA IgG2a level in serum at 200 ug, sc using liposome encapsulat2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID1469606Immunostimulatory activity in human PBMC assessed as increase in TNF-alpha release at 2 uM after 18 hrs in presence of LPS by flow cytometry relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID77656Ability of I-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 0.01 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1817380Agonist activity at NOD2 in HEK-Blue hNOD2 cells assessed as fold increase in NFkappaB transactivation-mediated SEAP activity at 2 uM measured after 18 hrs by spectrophotometric analysis relative to control2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID112009Compound was tested for protective activity in mice infected with Klebsiella pneumoniae; compound is pyrogenic at 1 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthetic immunostimulants derived from the bacterial cell wall.
AID77657Ability of I-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 0.1 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1817401Immuno-adjuvant activity in NIH/OlaHsd mouse assessed as increase in ovalbumin specific Th1 associated IgG1 production in sera at 0.15 micromol administered subcutaneously on day 1 and as booster dose on day 21 and 28 with ovalbumin loaded liposomes by EL2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID1469608Immunostimulatory activity in human PBMC assessed as increase in IL-2 release at 2 uM after 18 hrs in presence of LPS by flow cytometry2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID113915Tested for antibody response of mice injected with Bovine serum Albumin(BSA) at 50 ug/dose in experiment 11982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
AID78213Ability of I-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 0.01 ug/mL concentration in expt 11983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID615244Toxicity in human THP1 cells assessed TNF-alpha release at 20.2 uM after 3 to 24 hrs by sandwich ELISA2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
AID1817386Immunostimulatory activity in human PBMC cells assessed as increase in LPS-induced IL-6 production at 2 uM incubated for 18 hrs by flow cytometry analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID166924Febrile responses of compound was measured in rabbit after iv injection at the dose of 1 mg/kg1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides.
AID1469595Agonist activity at human NOD2 expressed in HEK-Blue cells assessed as induction of NF-kB transcriptional activity at 2 uM after 18 hrs by SEAP reporter gene assay relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID103642Compound was evaluated by Limulus amoebocyte lysate test; positive at 100 ug/mL1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthetic immunostimulants derived from the bacterial cell wall.
AID78216Ability of I-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 1 ug/mL concentration in expt 11983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1469613Immunoadjuvant activity in ovalbumin-induced NIH/OlaHsd mouse model of adjuvancy assessed as induction of ovalbumin-specific humoral immune response by measuring increase in anti-OVA IgG level in serum at 200 ug, sc using liposome encapsulated compound me2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID78214Ability of I-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 0.1 ug/mL concentration in expt 11983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID615229Immunomodulatory effect in human THP1 cells assessed as increase in LPS-induced TNF-alpha release after 24 hrs by sandwich ELISA relative to LPS2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
AID1469602Immunostimulatory activity in human PBMC assessed as increase in TNF-alpha release at 2 uM after 18 hrs by flow cytometry2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID78238Ability of P-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 0.01 ug/mL concentration in expt 21983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1817384Immunostimulatory activity in human PBMC cells assessed as increase in TNF-alpha production at 2 uM incubated for 18 hrs by flow cytometry analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID78240Ability of P-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 0.1 ug/mL concentration in expt 31983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1817381Immunostimulatory activity in human PBMC cells assessed as increase in IL-8 production at 2 uM incubated for 18 hrs by flow cytometry analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID615242Cytotoxicity against human PBMC assessed as LDH release at 20.2 uM2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
AID74893Antibody response to the compound was determined in guinea pigs1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis of fluorescent muramyl dipeptide congeners. 2.
AID167694Compound was tested for pyrogenicity in the rabbit; pyrogenic at 100 ug/mL.1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthetic immunostimulants derived from the bacterial cell wall.
AID615243Toxicity in human THP1 cells assessed TNF-alpha release at 20.2 uM after 24 hrs by sandwich ELISA2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
AID1297588Agonist activity at NOD2 receptor (unknown origin) expressed in HEK-Blue cells assessed as NF-kappaB transcriptional activity after 18 hrs by secreted embryonic alkaline phosphatase reporter gene assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Structural requirements of acylated Gly-l-Ala-d-Glu analogs for activation of the innate immune receptor NOD2.
AID77662Ability of L,L-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 1 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID615228Immunomodulatory effect in human THP1 cells assessed as increase in LPS-induced TNF-alpha release at 200 uM after 24 hrs by sandwich ELISA relative to LPS2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
AID113918Tested for antibody response of mice injected with Bovine serum Albumin(BSA) at 50 ug/dose in experiment 41982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
AID615226Immunomodulatory effect in human THP1 cells assessed as increase in LPS-induced TNF-alpha release at 0.2 uM after 24 hrs by sandwich ELISA relative to LPS2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
AID1469611Immunostimulatory activity in human PBMC assessed as increase in IFNgamma release at 2 uM after 18 hrs in presence of LPS by flow cytometry2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID1469596Agonist activity at human NOD1 expressed in HEK-Blue cells assessed as induction of NF-kB transcriptional activity at 20 uM after 18 hrs by SEAP reporter gene assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID113917Tested for antibody response of mice injected with Bovine serum Albumin(BSA) at 50 ug/dose in experiment 31982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
AID78218Ability of I-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 10 ug/mL concentration in expt 21983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID77661Ability of L,L-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 0.1 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID111818Compound was tested for antibody titer in mice after injection with antigen in saline; compound is pyrogenic at 1 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthetic immunostimulants derived from the bacterial cell wall.
AID75521Adjuvant activity was determined by the ability of compound to stimulate delayed hypersensitivity by intradermal injection of 10 ug of ovalbumin after 48 hr in guinea pigs1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Synthesis of fluorescent muramyl dipeptide congeners. 2.
AID133006Adjuvant activity was measured after sc administration in phosphate buffer saline (PBS) to mice with BSA and expressed as primary response1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides.
AID102708Mitogenic activity is evaluated in vitro against splenocyte culture from C58 mice; mitogenic1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Glycolipids as potential immunologic adjuvants.
AID77659Ability of I-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 10 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID113913Tested for antibody response of mice injected with Bovine serum Albumin(BSA) at 5 ug/dose in experiment 51982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
AID1469607Immunostimulatory activity in human PBMC assessed as increase in IL-6 release at 2 uM after 18 hrs in presence of LPS by flow cytometry relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID77669Ability of P-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 0.1 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID78221Ability of L,L-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 1 ug/mL concentration in expt 41983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1817382Agonist activity at NOD2 in HEK-Blue hNOD2 cells assessed as increase in NFkappaB transactivation-mediated SEAP activity measured after 18 hrs by spectrophotometric method2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID1469591Agonist activity at human NOD2 expressed in HEK-Blue cells assessed as induction of NF-kB transcriptional activity after 18 hrs by SEAP reporter gene assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID1817405Agonist activity at NOD1 in HEK-Blue hNOD2 cells assessed as increase in NFkappaB transactivation-mediated SEAP activity measured after 18 hrs by spectrophotometric method2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID113912Tested for antibody response of mice injected with Bovine serum Albumin(BSA) at 5 ug/dose in experiment 11982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
AID77658Ability of I-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 1 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID77660Ability of L,L-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 0.01 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1469610Immunostimulatory activity in human PBMC assessed as increase in IL-17A release at 2 uM after 18 hrs in presence of LPS by flow cytometry2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID113919Tested for antibody response of mice injected with Bovine serum Albumin(BSA) at 50 ug/dose in experiment 51982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
AID615241Cytotoxicity against human THP1 cells assessed as LDH release at 20.2 uM2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
AID1817388Immunostimulatory activity in human PBMC cells assessed as increase in LPS-induced TNF-alpha production at 2 uM incubated for 18 hrs by flow cytometry analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID78222Ability of L,L-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 10 ug/mL concentration in expt 51983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1297587Agonist activity at NOD1 receptor (unknown origin) expressed in HEK-Blue cells assessed as NF-kappaB transcriptional activity at 20 uM after 18 hrs by secreted embryonic alkaline phosphatase reporter gene assay2016European journal of medicinal chemistry, Jun-30, Volume: 116Structural requirements of acylated Gly-l-Ala-d-Glu analogs for activation of the innate immune receptor NOD2.
AID94070Protective activity against Klebsiella pneumoniae was measured as difference between the percentage of survivors in treated group and its respective control group1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides.
AID74757Compound was tested for delayed hypersensitivity in guinea pig after administration in a water in oil emulsion; compound is pyrogenic at 1 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthetic immunostimulants derived from the bacterial cell wall.
AID78215Ability of I-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 0.1 ug/mL concentration in expt 21983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1817383Immunostimulatory activity in human PBMC cells assessed as increase in IL-1beta production at 2 uM incubated for 18 hrs by flow cytometry analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID77663Ability of L,L-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 10 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID615225Immunomodulatory effect in human THP1 cells assessed as increase in LPS-induced TNF-alpha release at 20.2 uM after 24 hrs by sandwich ELISA relative to LPS2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
AID1469597Agonist activity at human NOD2 expressed in HEK-Blue cells assessed as induction of NF-kB transcriptional activity at 2 uM after 18 hrs in presence of NOD2 antagonist GSK-669 by SEAP reporter gene assay2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID78239Ability of P-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 0.01 ug/mL concentration in expt 31983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1817385Immunostimulatory activity in human PBMC cells assessed as increase in LPS-induced IL-8 production at 2 uM incubated for 18 hrs by flow cytometry analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID78219Ability of L,L-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 0.01 ug/mL concentration in expt 41983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID113914Tested for antibody response of mice injected with Bovine serum Albumin(BSA) at 5 ug/dose in experiment 61982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Synthesis and immunoadjuvant activities of 2-acetamido-5-O-acetyl-6-O-acyl-2-deoxy-3-O-[(R)-2-propionyl-L-alanyl-D- isoglutamine]-D-glucofuranoses as potential prodrug forms of 6-O-Acyl Derivatives of N-acetylmuramyl dipeptide.
AID1469605Immunostimulatory activity in human PBMC assessed as increase in IL-10 release at 2 uM after 18 hrs in presence of LPS by flow cytometry relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID77668Ability of P-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 0.01 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID78220Ability of L,L-MDP to inhibit migration of cultured guinea pig peritoneal exudate macrophages at 0.1 ug/mL concentration in expt 41983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID119459Compound was tested for [3H]- -thymidine uptake in mouse spleen cell cultures; compound is pyrogenic at 1 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Synthetic immunostimulants derived from the bacterial cell wall.
AID1469594Cytotoxicity against HEK-Blue cells over-expressing NOD2 assessed as residual metabolic activity at 20 uM after 18 hrs by CellTiter 96 aqueous one solution cell proliferation assay relative to control2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID122574Geometric mean titer of mice receiving 50 ug compound along with vaccine was determined after 21 days1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Glycolipids as potential immunologic adjuvants.
AID77670Ability of P-MDP to induce spreading of cultured guinea pig peritoneal exudate macrophages at 1 ug/mL concentration1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Synthesis of a biologically active fluorescent muramyl dipeptide congener.
AID1469603Immunostimulatory activity in human PBMC assessed as increase in IL-6 release at 2 uM after 18 hrs by flow cytometry2018Journal of medicinal chemistry, 04-12, Volume: 61, Issue:7
Discovery of Nanomolar Desmuramylpeptide Agonists of the Innate Immune Receptor Nucleotide-Binding Oligomerization Domain-Containing Protein 2 (NOD2) Possessing Immunostimulatory Properties.
AID1817379Immunostimulatory activity in human PBMC cells assessed as increase in IL-6 production at 2 uM incubated for 18 hrs by flow cytometry analysis2021Journal of medicinal chemistry, 06-10, Volume: 64, Issue:11
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their
AID137601Adjuvant activity was measured after sc administration in phosphate buffer saline (PBS) to mice with BSA and expressed as secondary response1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Apyrogenic, adjuvant-active N-acetylmuramyl-dipeptides.
AID615230Immunomodulatory effect in human PBMC cells assessed as increase in LPS-induced TNF-alpha release at 20.2 uM after 24 hrs by sandwich ELISA2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Design, synthesis and biological evaluation of novel desmuramyldipeptide analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (60.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (30.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 91.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index91.87 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index158.01 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (91.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
ConditionIndicatedRelationship StrengthStudiesTrials